Mekanistic Therapeutics is developing MTX-531, a first-in-class small molecule that dual-inhibits PI3K and EGFR pathways to combat resistance in PIK3CA mutant cancers. This targeted approach enhances therapeutic efficacy while minimizing toxicity, offering a promising solution for patients facing multiple solid tumor types.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
PIK3CA is a frequently mutated gene in solid cancers, including head and neck, lung, breast, and gastrointestinal malignancies. Cancer cells often develop resistance to PI3K inhibitors through mutations in the PI3K pathway or activation of alternative signaling pathways, rendering these inhibitors ineffective over time.
Solution
Mekanistic Therapeutics is developing MTX-531, a first-in-class small molecule that functions as a dual inhibitor of PI3K and EGFR pathways. By inhibiting EGFR, MTX-531 mitigates the need to escalate PI3K dosages, potentially reducing toxicity and broadening the therapeutic index. This targeted approach aims to overcome resistance mechanisms in PIK3CA mutant cancers, enhancing therapeutic efficacy and yielding more durable anti-tumor results. MTX-531 is designed to potentiate the efficacy of established treatments and exhibits significant synergy with RAS pathway inhibitors, radiation therapy, and immunotherapy.
Target Audience
The primary target audience includes patients with PIK3CA and KRAS mutant cancers across various solid tumor types, as well as oncologists and researchers focused on overcoming resistance to PI3K inhibitors.
Features
- Dual inhibition of PI3K and EGFR signaling pathways
- Circumvents hyperglycemia induction, enhancing the safety margin
- Synergistic activity with RAS pathway inhibitors, radiation therapy, and immunotherapy
- Applicable across multiple cancer indications, including head and neck, breast, lung, and gastrointestinal cancers
- Complete regressions observed in multiple preclinical models
- Selected for the NCI’s NExT program to accelerate clinical development